Next Article in Journal
Association with AflR in Endosomes Reveals New Functions for AflJ in Aflatoxin Biosynthesis
Next Article in Special Issue
Cloning and Characterization of a Hybridoma Secreting a 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-Specific Monoclonal Antibody and Recombinant F(ab)
Previous Article in Journal
Binding of Hanatoxin to the Voltage Sensor of Kv2.1
Previous Article in Special Issue
MHC Class II and Non-MHC Class II Genes Differentially Influence Humoral Immunity to Bacillus anthracis Lethal Factor and Protective Antigen
Open AccessArticle

Sheep Monoclonal Antibodies Prevent Systemic Effects of Botulinum Neurotoxin A1

1
Tufts Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA
2
Bioventix Limited, Farnham Surrey, UK
*
Author to whom correspondence should be addressed.
Toxins 2012, 4(12), 1565-1581; https://doi.org/10.3390/toxins4121565
Received: 22 November 2012 / Revised: 13 December 2012 / Accepted: 13 December 2012 / Published: 19 December 2012
(This article belongs to the Special Issue Toxin-Antibody Interactions)
Botulinum neurotoxin (BoNT) is responsible for causing botulism, a potentially fatal disease characterized by paralysis of skeletal muscle. Existing specific treatments include polyclonal antisera derived from immunized humans or horses. Both preparations have similar drawbacks, including limited supply, risk of adverse effects and batch to batch variation. Here, we describe a panel of six highly protective sheep monoclonal antibodies (SMAbs) derived from sheep immunized with BoNT/A1 toxoid (SMAbs 2G11, 4F7) or BoNT/A1 heavy chain C-terminus (HcC) (SMAbs 1G4, 5E2, 5F7, 16F9) with or without subsequent challenge immunization with BoNT/A1 toxin. Although each SMAb bound BoNT/A1 toxin, differences in specificity for native and recombinant constituents of BoNT/A1 were observed. Structural differences were suggested by pI (5E2 = 8.2; 2G11 = 7.1; 4F7 = 8.8; 1G4 = 7.4; 5F7 = 8.0; 16F9 = 5.1). SMAb protective efficacy vs. 10,000 LD50 BoNT/A1 was evaluated using the mouse lethality assay. Although not protective alone, divalent and trivalent combinations of SMabs, IG4, 5F7 and/or 16F9 were highly protective. Divalent combinations containing 0.5–4 μg/SMAb (1–8 μg total SMAb) were 100% protective against death with only mild signs of botulism observed; relative efficacy of each combination was 1G4 + 5F7 > 1G4 + 16F9 >> 5F7 + 16F9. The trivalent combination of 1G4 + 5F7 + 16F9 at 0.25 μg/SMAb (0.75 μg total SMAb) was 100% protective against clinical signs and death. These results reflect levels of protective potency not reported previously. View Full-Text
Keywords: botulinum neurotoxin; botulinum toxin; BoNT; BoNT/A1; BoNT/A2; monoclonal antibodies; sheep monoclonal antibodies; immunotherapy; passive immunization; botulism botulinum neurotoxin; botulinum toxin; BoNT; BoNT/A1; BoNT/A2; monoclonal antibodies; sheep monoclonal antibodies; immunotherapy; passive immunization; botulism
Show Figures

Figure 1

MDPI and ACS Style

Mukherjee, J.; McCann, C.; Ofori, K.; Hill, J.; Baldwin, K.; Shoemaker, C.B.; Harrison, P.; Tzipori, S. Sheep Monoclonal Antibodies Prevent Systemic Effects of Botulinum Neurotoxin A1. Toxins 2012, 4, 1565-1581.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop